CLINICAL TRIALS AND OBSERVATIONS A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia
نویسندگان
چکیده
1From the Service d’Hématologie, Hôtel Dieu, Nantes, France; 2H. Lee Moffitt Cancer Center & Research Institute, University of South Florida, Tampa; 3Service des Maladies du Sang, Hôpital du Haut Leveque, Pessac, France; 4Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands; 5Service des Maladies du Sang, Hôpital Edouard Herriot, Lyon, France; 6Service d’Hématologie, Chu Purpan, Toulouse Cedex, France; 7Hématologie, Avicenne Hôpital, Paris, France; 8Johnson & Johnson Pharmaceutical Research & Development, Raritan, NJ; and 9Adult Leukemia Program, Dana-Farber Cancer Institute, Boston, MA
منابع مشابه
CLINICAL TRIALS AND OBSERVATIONS A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia
1H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL; 2Greenebaum Cancer Center, University of Maryland, Baltimore; 3Division of Hematology, Stanford Cancer Center, CA; 4Weill Medical College, Cornell University, New York, NY; 5James P. Wilmot Cancer Center, University of Rochester, NY; 6Mayo Clinic, Rochester, MN; 7Blood and Marrow Transplant Group of Ge...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide
1Division of Hematologic Malignancies, Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, MD; 2Department of Oncology, Mayo Clinic College of Medicine, Rochester, MN; 3Department of Hematology/Oncology, New York Presbyterian Hospital, Cornell Medical Center, New York; 4Bone Marrow Transplant Group of Georgia, Atlanta; 5Investigational Drug Branch, Cancer Therapy Evaluation Program, National ...
متن کاملCLINICAL TRIALS AND OBSERVATIONS A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia
The interaction of acute myeloid leukemia (AML) blasts with the leukemic microenvironment is postulated to be an important mediator of resistance to chemotherapy and disease relapse. We hypothesized that inhibition of the CXCR4/CXCL12 axis by the small molecule inhibitor, plerixafor, would disrupt the interaction of leukemic blasts with the environment and increase the sensitivity of AML blasts...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia
Activating mutations of FMS-like tyrosine kinase 3 (FLT3) are present in approximately 30% of patients with de novo acute myeloid leukemia (AML) and are associated with lower cure rates from standard chemotherapy-based treatment. Targeting the mutation by inhibiting the tyrosine kinase activity of FLT3 is cytotoxic to cell lines and primary AML cells harboring FLT3 mutations. Successful FLT3 in...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma
Patients with multiple myeloma (MM) with mutated RAS are less likely to respond to chemotherapy and have a shortened survival. Therefore, targeting RAS farnesylation may be a novel approach to treatment of MM. We evaluated the activity and tolerability of the farnesyltransferase (FTase) inhibitor tipifarnib (Zarnestra) in a phase 2 trial as well as its ability to inhibit protein farnesylation a...
متن کامل